Koers BIOLASE Inc Nasdaq
Aandelen
US0909111082
Geavanceerde medische apparatuur & technologie
Omzet 2024 * | 51,5 mln. 48,1 mln. | Omzet 2025 * | 55,5 mln. 51,84 mln. | Marktkapitalisatie | 5,04 mln. 4,71 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -8 mln. -7,47 mln. | Nettowinst (verlies) 2025 * | -5 mln. -4,67 mln. | EV/omzet 2024 * | 0,1 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 0,09 x |
K/w-verhouding 2024 * |
-0,47
x | K/w-verhouding 2025 * |
-1,38
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99,67% |
Recentste transcriptie over BIOLASE Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
John Beaver
CEO | Chief Executive Officer | 62 | 01-10-17 |
Director of Finance/CFO | 53 | 01-02-21 | |
Steven Sandor
COO | Chief Operating Officer | 44 | 01-04-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jonathan Lord
CHM | Chairman | 69 | 01-08-14 |
John Beaver
CEO | Chief Executive Officer | 62 | 01-10-17 |
Director/Board Member | 73 | 16-08-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+7,76% | 220 mld. | |
+5,92% | 183 mld. | |
+9,98% | 133 mld. | |
+25,45% | 107 mld. | |
-1,86% | 63,05 mld. | |
+12,41% | 51,74 mld. | |
+3,96% | 50,47 mld. | |
-0,56% | 40,91 mld. | |
+24,17% | 31,91 mld. |